2018
DOI: 10.1016/j.jval.2018.04.569
|View full text |Cite
|
Sign up to set email alerts
|

The Cost-Effectiveness of Ustekinumab Compared to Infliximab And Adalimumab in Adult Patients with Moderate-Severe Crohn's Disease (Tnf Naïve Population)

Abstract: included same-day costs, costs for GERD-related procedures and any LF-related complications that occurred within 3 months after LF at a patient level. The UR of LF was calculated as the number of LF episodes divided by the total number of GERD patient-years throughout study period. ReSultS: 8,233 LF episodes among 8,197 patients were included in the analysis (7, and 1,093 Medicare-insured [MI]). The mean (standard deviation

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles